Positive results reported from Ebola vaccine trial in Liberia
The study tests the effectiveness and safety of the cAd3-EBOZ candidate vaccine, which was co-created by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases (NIAID), and the VSV-ZEBOV candidate vaccine, which was created by the Public Health Agency of Canada.
The first stage of the Phase 2 clinical trial involved more than 600 people in Liberia. Trial volunteers were randomly assigned to injections of a placebo, cAd3-EBOZ or VSV-ZEBOV in the double-blind study, meaning neither the volunteers nor the staff knew which injection they were receiving or injecting.
“We are grateful to the Liberian people who volunteered for this important clinical trial and encouraged by the study results seen with the two investigational Ebola vaccine candidates,” NIAID Director Anthony Fauci said. “Now we must move forward to adapt and expand the study so that ultimately we can determine whether these experimental vaccines can protect against Ebola virus disease and therefore be used in future Ebola outbreaks.”
The trial was accomplished thanks to the Partnership for Research on Ebola Vaccines in Liberia and NIAID, a branch of the National Institutes of Health.